Loading...

Gelesis Holdings, Inc.

GLS•NYSE
Healthcare
Biotechnology
$0.16
$0.00(0.00%)

Gelesis Holdings, Inc. (GLS) Stock Overview

Explore Gelesis Holdings, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for GLSStats details for GLS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for GLSAnalyst Recommendations details for GLS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

CEO

Mr. Yishai Zohar

Employees

93

Headquarters

501 Boylston Street, Boston, MA

Founded

2022

Frequently Asked Questions

;